Updates in Management for Local Regionally Advanced Squamous Cell Carcinoma

Abstract

The management of locoregionally-advanced cutaneous squamous cell carcinoma (laCSCC) is complex and requires a multidisciplinary approach, combining surgical resection, radiotherapy, and systemic therapies. Innovations in immunotherapy, particularly with checkpoint inhibitors cemiplimab and pembrolizumab, have shown promising overall and durable response rates and are now first-line therapies for laCSCC. Ongoing and future studies will help determine which patients should be considered for neoadjuvant or adjuvant immunotherapy, as well as which patients may safely deescalate the extent of surgery such as with lymph node dissection.

Keywords: Cemiplimab; Check point inhibitor; Locally advanced cutaneous squamous cell carcinoma; Neoadjuvant therapy; Pembrolizumab.